Chronic Granulomatous Disease (CGD) is a rare, inherited immunodeficiency caused by mutations in one or more components of the NADPH oxidase complex. This defect compromises the ability of phagocytes ...
Prime Medicine reports positive initial Phase 1/2 trial results for PM359, showing safety and efficacy in treating Chronic Granulomatous Disease. Prime Medicine, Inc. has announced positive initial ...
BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo treatments capable of precisely and durably engineering the hematopoietic system ...
7monon MSN
Prime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD Data
Prime Medicine Inc. (NASDAQ:PRME) is one of the best hot stocks to buy according to Wall Street analysts. In May, Prime Medicine announced a strategic restructuring, which included a reprioritization ...
-- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- - ...
Prime Medicine announces positive Phase 1/2 data for PM359, leadership changes, and strategic pipeline prioritization, focusing on liver diseases. Prime Medicine, Inc. announced initial positive data ...
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
First ever clinical evaluation of an in vivo HSC-directed gene insertion therapy aims to restore immune function for people living with X-linked chronic granulomatous disease Ensoma, an in vivo ...
At just three months old, Virginia’s life changed forever when she was diagnosed with Chronic Granulomatous Disease (CGD)—a rare and serious disorder affecting the body’s white blood cells. The only ...
Ensoma Inc. has obtained IND clearance from the FDA for its lead program EN-374 in X-linked chronic granulomatous disease (X-CGD). A phase I/II trial in both adult and pediatric patients with X-CGD is ...
Shares of Prime Medicine (NASDAQ:PRME) fell on Monday after it said that it will stop development in X-linked chronic granulomatous disease and is exploring options to continue development of its ...
Ensoma Inc.’s lead program, EN-374, has been granted orphan drug and rare pediatric disease designations by the FDA for the treatment of X-linked chronic granulomatous disease. Ensoma anticipates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results